VolitionRx Showcases Groundbreaking Research at NA Conference on Lung Cancer

VolitionRx Limited, a leading company in the field of epigenetics, recently made a notable appearance at the North American Conference on Lung Cancer (NACLC) held in Chicago, showcasing two critical research abstracts. These presentations centered around the utilization of their innovative Nu.Q® Cancer assays, aimed at optimizing the management of lung cancer patients.

The first presentation featured a study led by Professor Lea Payen from Claude Bernard University in Lyon, France. This extensive research examined the prognostic value of circulating H3K27Me3-nucleosomes in patients recently diagnosed with lung cancer. According to Professor Payen, the findings showed an increase in Nu.Q®-H3K27Me3 levels corresponding to the stages of cancer, establishing it as a vital independent prognostic marker for overall survival. This discovery provides a practical method for refining risk assessments in cases where ctDNA is negative, offering crucial insights that can inform clinical decisions, particularly regarding personalized therapeutic approaches.

Professor Payen expressed excitement over the possibilities presented by this research, stating, "This large-scale study demonstrates that Nu.Q®-H3K27Me3 levels increase with cancer disease stages and importantly, that their level at diagnosis emerges as an independent prognostic biomarker for overall survival." The team has already placed its first order for the Nu.Q® Cancer assays, indicating a positive step toward integrating this testing into routine clinical practices within their hospital network.

The second abstract, co-led by Dr. Pei-Hsing Chen from the National Taiwan University, focused on the significance of pre-operative nucleosome liquid biopsies for risk stratification in lung cancer. Dr. Chen highlighted a key finding indicating that the assessment of preoperative H3K27Me3-nucleosomes through a simple blood test could identify Non-Small Cell Lung Cancer patients who may benefit from intensified monitoring or secondary treatments. High levels of H3K27Me3-nucleosomes were associated with poorer recurrence-free and overall survival rates, while lower levels indicated better outcomes. This insight has the potential to guide systemic therapy decisions for high-risk patients.

Dr. Andrew Retter, Chief Medical Officer at Volition, commented on the importance of the Nu.Q® Cancer platform, stating, "This technology represents a significant advancement in the management of lung cancer patients, providing clinicians with an additional tool to enhance precision in treatment selection and monitoring." He emphasized that the research conducted in collaboration with teams in Lyon and Taiwan continues to support the utilization of Nu.Q® Cancer technology, empowering clinicians to make informed treatment decisions and enabling better patient outcomes over the course of their cancer journey.

The NACLC, hosted by the International Association for the Study of Lung Cancer, prides itself on being the only global organization solely dedicated to lung cancer research, boasting a membership of nearly 9,000 specialists in over 100 countries. This conference serves as a significant platform for sharing cutting-edge developments and fostering collaboration within the lung cancer research community.

VolitionRx is a multinational organization focused on advancing epigenetics science, aiming to enhance early detection and monitoring of diseases, including various types of cancer through innovative blood tests. The company operates with the mission of saving lives by enabling earlier diagnostics and monitoring, ultimately aimed at improving the quality of life for patients.

With its operations rooted in Belgium and additional locations in the United States and London, VolitionRx is poised to make significant contributions to the field of cancer detection and management, setting the stage for future innovations that could reshape patient care in oncology. As the integration of Nu.Q® into clinical practice nears reality, the potential impact of such advancements reaffirms Volition's commitment to enhancing patient-centered care.

For more information on VolitionRx and its latest innovations, interested parties can refer to their official website or contact the company representatives for inquiries regarding partnerships or media engagement.